 |
|
|
| |
HIV-1 from antiretroviral-naïve and experienced patients lack capsid substitutions
associated with GS-6207 in vitro resistance
|
| |
| |
EACS: Single Doses of Long-Acting Capsid Inhibitor GS-6207 Administered by Subcutaneous Injection Are Safe and Efficacious in People Living With HIV - (11/12/19)
EACS: GS-6207 Long Acting Capsid Inhibitor Safety & PK Subcutaneous - (11/12/19)
EACS 2019 Nov 6-9 Basel
Reported by Jules Levin
Anne-Genevieve Marcelin1,2, Charlotte Charpentier3,4, Aude Jary1,2, Marine Perrier3,4, Vincent Calvez1,2, and Diane Descamps 3,4
Anne-Genevieve Marcelin disclosed no conflict of interest
Email : Anne-Genevieve Marcelin@aphp.fr
1 Sorbonne Universite, INSERM UMR 1136, Paris; 2 Laboratoire de Virologie, AP-HP, Hopital Pitie-Salpetriere, Paris, France;
3 Universite de Paris, INSERM UMR 1137 IAME, Paris, France; 4 Laboratoire de Virologie, AP-HP, Hopital Bichat-Claude Bernard, Paris, France
Here we studied the prevalence of CA mutations associated with in vitro resistance to GS-6207 in antiretroviral therapy (ART)-naïve or -experienced PLWH. Genetic variations in gag naturally occur depending on the HIV subtypes, immune pressure (CTL epitopes), and prior use of HIV protease (PR) inhibitors (PIs), as gag is the substrate for PR
|
| |
|
|
|
|
|
